Satellos Bioscience (MSLE) Prepaid Assets (2023 - 2026)

Satellos Bioscience (MSLE) posted quarterly Prepaid Assets of $4.6 million for Q1 2026, up 20.43% quarter-over-quarter from $3.8 million in Q4 2025.

Satellos Bioscience (MSLE) Prepaid Assets (2023 - 2026) Analysis & Trends

Satellos Bioscience (MSLE) has reported Prepaid Assets for 4 consecutive years, with $4.6 million the latest figure, recorded in Q1 2026.

In Q1 2026, Prepaid Assets changed N/A year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $4.6 million (changed N/A YoY), while the FY2025 annual figure was $3.8 million, up 116.14% from the prior year.
Prepaid Assets improved to $4.6 million in Q1 2026 per MSLE's latest filing, from $3.8 million in the prior quarter.
Across five years, Prepaid Assets topped out at $4.6 million in Q1 2026 and bottomed at $108711.3 in Q4 2023.
Historically, Prepaid Assets has averaged $2.6 million across 4 years, with a median of $2.8 million in 2025.
Annual changes were most pronounced in 2024 — Prepaid Assets soared 1567.29% — and 2025, when it jumped 109.87%.
Satellos Bioscience's Prepaid Assets stood at $108711.3 in 2023, then jumped by 1567.29% to $1.8 million in 2024, then surged by 109.87% to $3.8 million in 2025, then gained by 20.43% to $4.6 million in 2026.
Business Quant data shows MSLE's Prepaid Assets at $4.6 million in Q1 2026, $3.8 million in Q4 2025, and $1.8 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Satellos Bioscience	206.75 Mn	206.75 Mn	-

Download Data